- United States
- /
- Biotech
- /
- NasdaqGM:MIRM
Exploring 3 High Growth Tech Stocks in the US Market
Reviewed by Simply Wall St
In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion within a stable and upward-trending market environment.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.31% | 30.44% | ★★★★★★ |
TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
Alkami Technology | 20.45% | 85.16% | ★★★★★★ |
Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
AVITA Medical | 27.74% | 55.36% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.76% | 58.08% | ★★★★★★ |
Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 240 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Mirum Pharmaceuticals (NasdaqGM:MIRM)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $2.30 billion.
Operations: Mirum Pharmaceuticals focuses on developing and commercializing therapies for rare and orphan diseases, generating $336.89 million in revenue from its pharmaceuticals segment.
Mirum Pharmaceuticals, despite its current unprofitability, is navigating a promising trajectory with an expected revenue growth of 21.1% annually, outpacing the US market's 8.4%. This growth is bolstered by its recent FDA approval for Ctexli, a groundbreaking treatment for CTX, highlighting its commitment to addressing rare diseases with significant unmet medical needs. Moreover, the company's R&D focus remains robust as evidenced by substantial investments aimed at expanding its product pipeline and enhancing drug efficacy—crucial steps toward profitability and market relevance in the competitive biotech landscape.
- Navigate through the intricacies of Mirum Pharmaceuticals with our comprehensive health report here.
Alkami Technology (NasdaqGS:ALKT)
Simply Wall St Growth Rating: ★★★★★★
Overview: Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States and has a market capitalization of approximately $2.71 billion.
Operations: Alkami Technology generates revenue primarily from its Internet Software & Services segment, which accounts for $333.85 million. The company focuses on providing cloud-based digital banking solutions within the U.S. market.
Alkami Technology, Inc. is navigating a transformative path in the digital banking sector, marked by a robust 20.4% annual revenue growth and strategic partnerships aimed at enhancing user experiences and financial security. The company's recent collaboration with BioCatch to thwart $54 million in fraudulent transactions underscores its commitment to innovative fraud prevention techniques. Furthermore, Alkami's R&D investments are pivotal, focusing on integrating cutting-edge technologies to maintain its competitive edge in a rapidly evolving market. This approach not only drives customer satisfaction through improved digital interactions but also positions Alkami for anticipated profitability with an expected earnings growth of 85.16% per year, reflecting its potential resilience and adaptability in the tech landscape.
- Click to explore a detailed breakdown of our findings in Alkami Technology's health report.
Evaluate Alkami Technology's historical performance by accessing our past performance report.
Intapp (NasdaqGS:INTA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Intapp, Inc., through its subsidiary Integration Appliance, Inc., offers AI-powered solutions across the United States, the United Kingdom, and internationally with a market cap of approximately $4.84 billion.
Operations: Intapp generates revenue primarily from its Software & Programming segment, amounting to $465.03 million. The company leverages AI-powered solutions to serve clients across various regions, including the United States and the United Kingdom.
Intapp stands out in the tech landscape, notably with its recent unveiling of Intapp DealCloud Activator at their annual event. This AI-driven platform is a game-changer in professional services, enhancing business development through real-time insights and behavioral science to optimize client lifecycle management. The company's commitment to innovation is further evidenced by substantial R&D investments, which have positioned them as a pivotal player in sector modernization. Moreover, the opening of a new R&D center in Lisbon underscores their dedication to global expansion and technological advancement. With revenue up 13.6% annually and an ambitious forecast for profitability within three years, Intapp is strategically poised for sustained growth amidst evolving market demands.
- Click here to discover the nuances of Intapp with our detailed analytical health report.
Understand Intapp's track record by examining our Past report.
Summing It All Up
- Click here to access our complete index of 240 US High Growth Tech and AI Stocks.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:MIRM
Mirum Pharmaceuticals
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Undervalued with high growth potential.
Market Insights
Community Narratives

